BlackRock Advisors’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

BlackRock Advisors’s Portfolio BLPH Stock Details BLPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-24	Closed	-$3K	–	3807
2015 Q2	$3K	Buy	24 +3	+14%	+$408	﹤0.01%	3684
2015 Q1	$3K	Buy	+21	New	+$3.27K	﹤0.01%	3584

Other funds holding BLPH

NMVA

New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock Advisors's BLPH Position: Q3 2015 in Review

BlackRock Advisors sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q3 2015, closing a stake of 24 shares — an estimated $3K sold.

BlackRock Advisors first reported a position in BLPH in Q1 2015 and held it in 2 quarters. The position peaked at $3K in Q2 2015. 15 funds tracked by Wall St. Rank hold BLPH as of Q3 2015.

BlackRock Advisors reported no remaining Bellerophon Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
BlackRock Advisors sold 24 Bellerophon Therapeutics, Inc. shares in Q3 2015, an estimated $3K.
BlackRock Advisors first reported a position in Bellerophon Therapeutics, Inc. in Q1 2015 and held it in 2 quarters.
BlackRock Advisors's Bellerophon Therapeutics, Inc. position peaked at $3K in Q2 2015.
15 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q3 2015.

Based on BlackRock Advisors's 13F filing for Q3 2015, filed 13 Nov 2015.